BBK Worldwide Introduces e-BinderSM 2 at the 47th Annual Meeting of the Drug Information Association in Chicago
BBK Worldwide has utilized a secure data “tunnel” that allows biopharmaceutical companies to leverage the power of the Apple® iPad® 2 cost-efficiently. BBK is introducing the e-BinderSM 2–an Apple iPad 2 specifically customized for the research and development community and its regulatory guidelines–at the Drug Information Association’s Annual Meeting commencing this week in Chicago.
One of the major barriers to implementing a franchise or multi-study communications program using the iPad 2–despite its convenience and effectiveness–is the risk of unpredictable monthly data costs associated with the use of a 3G network. BBK’s e-Binder 2 completely mitigates this risk. The e-Binder 2 deploys a proprietary virtual “tunnel” that permits only designated IP addresses to be accessible through a 3G network, with other sites available using aWi-Fi connection. “By identifying this global tunnel, BBK has enabled clients to deploy the e-Binder as a work tool and be confident that data consumption is for study-related activities,” said BBK Worldwide CEO Joan F. Bachenheimer.
Today, many study protocols undergo more than five amendments. As each country’s regulatory bodies approve these amendments, the content accessible through the e-Binder 2 can be updated electronically within minutes.
Earlier this month, BBK deployed 50 e-Binders to clinical research associates working throughout Eastern Europe and Latin America to drive enrollment for a multinational multiple sclerosis study.
BBK partners with sister company TCN e-Systems to deploy patient recruitment solutions via mobile and online technologies. Direct connections between the e-Binder and the sponsor’s web-based portals, as well as content updates, are managed by TCN e-Systems.
BBK will exhibit the e-Binder 2 and other technology solutions for patient recruitment at the 47th annual meeting of the Drug Information Association, 19 – 23 June 2011, in Chicago (booth # 1616).
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
